These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26585936)

  • 1. Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease.
    Mukhametov A
    Curr Top Med Chem; 2016; 16(12):1351-61. PubMed ID: 26585936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric inhibitors of the NS3 protease from the hepatitis C virus.
    Abian O; Vega S; Sancho J; Velazquez-Campoy A
    PLoS One; 2013; 8(7):e69773. PubMed ID: 23936097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
    Slater MJ; Amphlett EM; Andrews DM; Bamborough P; Carey SJ; Johnson MR; Jones PS; Mills G; Parry NR; Somers DO; Stewart AJ; Skarzynski T
    Org Lett; 2003 Nov; 5(24):4627-30. PubMed ID: 14627400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing and molecular docking of cyclic peptides against HCV NS3 protease.
    Masoud MS; Bukhari SA; Qasim M; Naqvi SAR; Ashfaq UA
    Pak J Pharm Sci; 2017 Sep; 30(5(Supplementary)):1965-1969. PubMed ID: 29105629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease.
    Avolio S; Summa V
    Curr Top Med Chem; 2010; 10(14):1403-22. PubMed ID: 20536420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus.
    Meeprasert A; Rungrotmongkol T; Li MS; Hannongbua S
    Curr Pharm Des; 2014; 20(21):3465-77. PubMed ID: 24001230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
    Venkatraman S; Velazquez F; Wu W; Blackman M; Madison V; Njoroge FG
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2151-5. PubMed ID: 20226659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
    Ren J; Ojeda I; Patel M; Johnson ME; Lee H
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to anti-HCV protease inhibitors.
    Thompson AJ; Locarnini SA; Beard MR
    Curr Opin Virol; 2011 Dec; 1(6):599-606. PubMed ID: 22440917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
    Bondada L; Rondla R; Pradere U; Liu P; Li C; Bobeck D; McBrayer T; Tharnish P; Courcambeck J; Halfon P; Whitaker T; Amblard F; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6325-30. PubMed ID: 24135727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.